Rapid clearance of Borrelia burgdorferi from the blood circulation

Abstract

Background

Borrelia burgdorferi is a tick-borne spirochete that causes Lyme borreliosis (LB). After an initial tick bite, it spreads from the deposition site in the dermis to distant tissues of the host. It is generally believed that this spirochete disseminates via the hematogenous route. Borrelia persica causes relapsing fever and is able to replicate in the blood stream. Currently the exact dissemination pathway of LB pathogens in the host is not known and controversially discussed.

Methods

In this study, we established a strict intravenous infection murine model using host-adapted spirochetes. Survival capacity and infectivity of host-adapted B. burgdorferi sensu stricto (Bbss) were compared to those of B. persica (Bp) after either intradermal (ID) injection into the dorsal skin of immunocompetent mice or strict intravenous (IV) inoculation via the jugular vein. By in vitro culture and PCR, viable spirochetes and their DNA load in peripheral blood were periodically monitored during a 49/50-day course post-injection, as well as in various tissue samples collected at day 49/50. Specific antibodies in individual plasma/serum samples were detected with serological methods.

Results

Regardless of ID or IV injection, DNA of Bp was present in blood samples up to day 24 post-challenge, while no Bbss was detectable in the blood circulation during the complete observation period. In contrast to the brain tropism of Bp, Bbss spirochetes were found in ear, skin, joint, bladder, and heart tissue samples of only ID-inoculated mice. All tested tissues collected from IV-challenged mice were negative for traces of Bbss. ELISA testing of serum samples showed that Bp induced gradually increasing antibody levels after ID or IV inoculation, while Bbss did so only after ID injection but not after IV inoculation.

Conclusions

This study allows us to draw the following conclusions: (i) Bp survives in the blood and disseminates to the host’s brain via the hematogenous route; and (ii) Bbss, in contrast, is cleared rapidly from the blood stream and is a tissue-bound spirochete.

Background

All known species of spiral-shaped bacteria (spirochetes) in the genus Borrelia are transmitted by ticks, except for B. recurrentis, which is transmitted by the human louse and leads to louse-borne relapsing fever (LBRF) [1]. Two groups of Borrelia stand out among these tick-borne species due to their prevalence as human pathogens [2, 3]. One group is spirochetes that are transmitted by fast-feeding argasid (soft) ticks of the genus Ornithodoros and cause tick-borne relapsing fever (TBRF). Among them, B. persica (Bp) is an important and prevalent pathogen of TBRF in humans [4] and is the main pathogen responsible for this disease in Central Asia and Middle East countries [5]. Clinically, recurrent episodes of high fever with (massive numbers of) spirochetes in the patient’s blood are a unique feature of the disease, whereas spirochetemia is not detected during afebrile periods [6, 7]. In addition, Bp causes infections in domestic dogs, cats [8] and, under experimental conditions, guinea pigs [9]. Assous et al. [10] detected borrelial organisms in blood specimens from mice four and six days after intraperitoneal (ip; intraabdominal) injection of blood samples from patients who had been diagnosed with having contracted a Bp infection. Furthermore, Addamiano & Babudieri [11] and Schwarzer et al. [12] discovered that Bp organisms reside in the brain tissue of infected mice late during the infection, while spirochetes were simultaneously not detectable in blood samples collected from the same animals. Despite this pathogenesis phenotype, little is known about the exact mechanisms how Bp crosses the endothelium barrier from the blood vessel into the host’s tissues. Similarly, the factors that are necessary to populate certain tissues types such as the brain are not known.

The other large group, Lyme borreliosis (LB) spirochetes, is transmitted by the slow-feeding ixodid (hard) ticks [2, 13–15]. Within the B. burgdorferi (sensu lato) complex, four genospecies have been identified as important human pathogens of LB. Borrelia burgdorferi sensu stricto (Bbss) is found predominantly in the USA and less often in Europe, while B. garinii, B. afzelii and B. bavariensis occupy extensive regions in Eurasia [16, 17]. After ixodid ticks have deposited the Borrelia organisms in the skin, increasing spirochete numbers are found around the tick bite site, and they may initiate an early inflammatory reaction that is clinically evident as a rash (erythema migrans, EM). During later stages of infection, B. burgdorferi organisms spread to distant locations, resulting in a multisystem infectious disease (e.g. carditis and chronic arthritis) [18–20]. Clinical manifestations are thought to show following Borrelia dissemination [21–23]. In this context, some authors [24, 25] hold the view that Borrelia spirochetes use the blood stream, in which B. burgdorferi organisms first enter the vasculature near the deposition site after the tick bite and subsequently exit the vasculature to various tissues. Positive spirochete cultures and/or DNA detection of B. burgdorferi in plasma or blood samples from LB patients during the early stage of illness [21, 22, 26–28] are used as arguments to support the hypothesis of hematogenous dissemination of the organism. Other studies suggest, however, that dissemination of B. burgdorferi occurs by tissue migration rather than by blood stream dissemination since live spirochetes have been found with the highest frequency in tissues closest to the site of tick exposure [29]. Similarly, other investigators reported varying numbers of spirochetes and distinguished several degrees of joint and cardiac inflammation, which were strongly related to the inoculation site, e.g. the shoulder region versus footpad in experimental mice [30]. If the LB borreliae spread to further tissues through the blood stream, a random distribution of infection would be anticipated. Consequently, any joint might show signs of inflammation after it has been invaded by spirochete organisms. However, studies show that tissues closest to the tick bite show a higher probability to become infected and inflamed. For example, Berglund et al. [31] observed that “bites in the head and neck region were more common among children than among adults and were associated with an increased risk of neuroborreliosis”. Given this contradictory scientific background, it is necessary to determine whether LB pathogens disseminate via the blood stream, tissue migration, or both.

Nevertheless, Lyme borreliae may appear and can be found in the blood stream. Immunodeficient animals that lack mature T and B cells and complement [32] are known to show a high burden of Bbss in their circulation due to their insufficient defense system [33–35]. The presence of spirochetes in the blood proves that the organisms may enter the circulation but is not an argument that spirochetes can actively leave the blood circulation and thus colonize distant sites of the body.

In the present study, we developed model by producing host-adapted Bp and Bbss in immunodeficient mice and investigated their viability and infectivity in the blood stream of immunocompetent mice after intradermal (ID) and strict intravenous (IV) inoculation. The study aimed to clarify the dissemination pathways. Furthermore, whether LB Borrelia can spread via the bloodstream to distant tissue sites and establish an infection exclusively by the haematogenic route.

Methods

Mice

Specific pathogen-free, 6- to 8-week-old female NOD-SCID (non-obese diabetic-severe combined immune deficiency) and 8- to 10-week-old female C3H/HeOuJ (immunocompetent) mice were purchased from Janvier Labs (Saint Berthevin Cedex, France) and Charles River (Sulzfeld, Germany), respectively. All mice used herein were maintained and handled at the animal facility of the Institute of Infectious Diseases and Zoonoses, Ludwig-Maximilians-Universität (Munich, Germany). Mice were introduced into the animal facility at least one week prior to experiments to ensure adequate acclimation to the new environment. Two to three days prior to spirochete exposure, blood was collected from these NOD-SCID and C3H/HeOuJ mice, and plasma samples were used as baseline controls. After the experiment, all mice were sacrificed by cervical dislocation under anesthesia with medetomidine (0.5 mg/kg) combined with midazolam (5 mg/kg) [36, 37].

Borrelial strains and cultivation conditions

Low-passage strains of Bp (LMU-C01; feline isolated, passage 2) and Bbss (N40; passage 4) were used for the infection of mice [12, 38, 39]. Frozen glycerol stocks of Bp were cultivated in Pettenkofer/LMU Bp medium at 37 °C [40], and those of Bbss were cultivated in commercial Barbour-Stoenner-Kelly H (BSK-H) complete medium with 6% rabbit serum (Sigma-Aldrich, Taufkirchen, Germany) at 33 °C [41]. Bacteria were counted with a dark-field microscope (10×/40; Leica DM2500; Leica Microsystems GmbH, Wetzlar, Germany) using a Petroff-Hausser counting chamber (Hausser Scientific, Horsham, Pennsylvania, USA). Bp and Bbss were grown for 6 to 7 days to reach concentrations of 2.0 × 10⁶ and 1.0 × 10⁷ viable spirochetes per ml of medium, respectively. Total inocula of 1.0 × 10⁵ viable/motile Bp or 1.0 × 10⁶ viable/motile Bbss organisms were prepared by adjusting the medium volume to 50 µl or 100 µl, respectively. All media used in this study contained no antibiotics, except for the media used for isolation of borreliae from blood samples, which contained 8 µg/ml kanamycin and 50 µg/ml rifampicin (Sigma-Aldrich), as described [42].

Generation of host-adapted Borrelia organisms using immunodeficient mice

Immunodeficient NOD-SCID mice were utilized to generate host-adapted Borrelia organisms due to their lack of mature T and B cells and complement. Compared to normal SCID mice, NOD-SCID mice have reduced macrophage and natural killer (NK) cell functions [32]. A flowchart with the timing of each sample and test is shown in Fig. 1. In the first step, six NOD-SCID mice each received intradermally 1.0 × 10⁵Bp or 1.0 × 10⁶Bbss organisms (as described above) in their shaven dorsal backs (disinfected with 70% ethanol). Thereafter, these six mice were randomly divided into two equal subgroups, and blood samples were collected via facial vein puncture every other day for each subgroup until day 17. To confirm successful infection, 30 µl blood samples were diluted and mixed with 500 µl of medium for examination of motile spirochetes using dark-field microscopy, followed by cultivation of Bp or Bbss in 5 ml of medium. In addition, the kinetics of the hematogenous spirochete load in the six NOD-SCID mice was documented with a qPCR test to determine the day of the largest bacterial load. A second separate group of animals consisting of five NOD-SCID mice was inoculated with an identical dose of spirochetes (Bp or Bbss), as described above. On the anticipated day with the highest bacterial load, anticoagulated peripheral blood was collected aseptically with S-Monovette 2.7-ml K3E (Sarstedt AG & Co., Nümbrecht, Germany) by cardiac puncture under anesthesia. All blood samples from these five mice injected with Bp or Bbss were pooled and subsequently checked for bacterial viability using a dark-field microscope. Aliquots from pooled blood samples were stored at − 30 °C for later qPCR analysis.

Fig. 1.

Timing of sampling and tests which were conducted with immunocompetent mice during the present study

Additional tissue samples collected from ears, skin (inoculation areal), tibiotarsal joints, spleens, urinary bladders, hearts, and brains were aseptically removed on the anticipated day. Samples were divided into equal parts. Half of each tissue sample was transferred to medium for bacterial culture, and the other half was stored at − 30 °C for qPCR testing.

Intradermal or strict intravenous injection of host-adapted Borrelia organisms into immunocompetent mice

Five C3H/HeOuJ mice served as negative control animals. These animals were anesthetized and received 100 µl of anticoagulated blood without Borrelia organisms collected from two non-infected NOD-SCID mice via strict IV injection into the jugular vein. Mice were monitored for five weeks; blood collection for plasma samples was performed once per week.

As scheduled, blood samples from individual immunodeficient NOD-SCID mice were collected and pooled together in the early morning, followed by microscopic inspection and aliquoting. Between approximately 10:00 h and 17:00 h, the pooled blood containing host-adapted spirochetes was then inoculated intravenously. Thereafter, intradermal injection was conducted in the evening. After the injection, the remaining pooled blood samples were inspected under dark-field microscopy and cultured in medium, and we confirmed the presence of motile spirochetes and their growth. Groups of C3H/HeOuJ mice received 100 µl of freshly pooled blood from five NOD-SCID mice, which contained host-adapted Borrelia spp. (Bp or Bbss), as described above. These 100 µl aliquots from the same blood pool were injected into the shaven dorsal back (ID, disinfected with 70% ethanol) or jugular vein (IV) of C3H/HeOuJ mice. Injection experiments with host-adapted Bbss organisms were repeated later with additional groups of C3H/HeOuJ mice (host-adapted organisms were obtained from another five NOD-SCID mice). All utilized C3H/HeOuJ mice (n = 33) were grouped as follows: 5 mice in the Bp-ID group and 6 mice in the Bp-IV group; 11 mice were allocated to Bbss-ID (5 in the first group; 6 in a second group); and 11 mice were allocated to Bbss-IV (5 in the first group; 6 in a second group).

The surgery for intravenous spirochete injection was carried out as follows. All mice were deeply anesthetized by IP injection of medetomidine (0.5 mg/kg), midazolam (5 mg/kg) and fentanyl (0.05 mg/kg) [36, 37]. The anesthesia protocol was the same for all mice. A warming pad (model #39DP; Braintree Scientific, Inc., Braintree, USA) was used to maintain the body temperature at 37 °C. Hair under the chin was removed by shaving, and this area was disinfected with 70% ethanol and air-dried. At a position slightly right of the body’s midline under the chin, an ~ 1 cm long incision was made into the skin, and the tissue was carefully dissected to obtain access to the right jugular vein. Using a stereomicroscope (Leica M60; Leica Microsystems GmbH) equipped with a Leica MC170 HD camera (Leica Microsystems GmbH) and two gooseneck lights (Leica LED3000 SLI; Leica Microsystems GmbH), connective tissue and fat were further removed without injuring the jugular vein. Splinter forceps (No. 310645; Henry Schein Vet GmbH, Hamburg, Germany) and eye forceps (No. 310174; Henry Schein Vet GmbH) were utilized during this procedure. The exposed vein and removed tissue were immersed in sterile physiological saline. By holding the jugular vein with a bulb-headed probe (No. 310335; Henry Schein Vet GmbH), two loop ligations were made around the vein with Surgicryl® PGA polyglycolic acid suture (SMI AG, St. Vith, Belgium). The up-ligation was completely closed, and the down-ligation was a loose knot fixed with Student Halsted-Mosquito Hemostats (No. 91309-12; Fine Science Tools GmbH, Heidelberg, Germany). An injection catheter was fully filled with sterile 0.9% saline (~ 13 µl). The jugular vein was positioned with two bulb-headed probes to avoid damage and bleeding. Vannas-style spring scissors (No. 15000-03; Fine Science Tools GmbH) were used to cut a 45° angle hole (up to down) into the jugular vein. A micro hook (blunt, No. 10062-12; Fine Science Tools GmbH) was a superb tool for opening and grabbing the vessel’s wall and for inserting the catheter. Intravenous injection was performed with an Alzet Mouse Jugular Catheter (No. 0007700; Durect Corporation, California, USA) with a 23-gauge Terumo Agani needle (Shanghai International Holding Corp. GmbH, Hamburg, Germany) attached to a 1 ml single-use syringe (Dispomed Witt oHG, Gelnhausen, Germany) filled with 140 µl of pooled blood from the immunodeficient donor mice. When ~ 9 mm of the catheter tip was introduced into the jugular vein, the down-ligation was closed and secured such that the catheter would not slip out from the vein. The down-placed bulb-headed probe was removed for adequate space and fluent injection. After attaching the 23-gauge needle (connected with the 1 ml syringe) to the exposed end of the catheter, 100 µl of blood was injected very slowly (~ 10 µl/min) into the vein. Thereafter, the needle was removed from the catheter, and a second 23-gauge needle connected with the 1 ml syringe filled with sterile 0.9% saline was subsequently attached to the catheter. The catheter was flushed with 50 µl of sterile saline. Then, the catheter tip was carefully pulled back and was still connected to the needle and syringe. At the same time, the down-ligation was entirely fastened, avoiding any blood loss into the tissue. The incision site was closed with an intracutaneous suture (4–5 single sutures) using 5/0 Monosyn® Easyslide (DS16; B. Braun Surgical SA, Barcelona, Spain). Atipamezole (2.5 mg/kg), flumazenil (0.5 mg/kg) and naloxone (1.2 mg/kg) [36, 37] were injected intraperitoneally. Standard aseptic techniques were employed during the complete procedure. Videos documenting the surgical progress and the strict IV injection of blood samples were recorded through 10×/1.6 objectives of the stereomicroscope.

Blood, plasma and serum sample collection and cultivation of spirochetes

After ID or IV injection, blood samples were collected via facial vein puncture from the C3H/HeOuJ mice. Two to four drops of blood were transferred directly into a Microvette 100 K3E (preparation K₃EDTA; Sarstedt AG & Co.). First blood samples were collected on day 6 post-infection (pi) (recovery time after surgery) and thereafter every three days until day 30 pi. After day 30 pi, additional blood samples were collected on days 37, 44, and 49/50 pi. Five microliters of blood from each mouse at each time point was stored for qPCR screening. Plasma samples were harvested from pooled blood in each IV or ID group by centrifugation at 350× g for 10 min at 23 °C. Serum samples were obtained from a large volume of blood sampled via cardiac puncture from each individual mouse under anesthesia on day 49/50 pi. Mice were collected because of technical reasons either on day 49 pi or on day 50 pi. All the samples were frozen at − 30 °C for subsequent tests.

Thirty microliters of pooled blood samples were used to monitor and cultivate spirochetes in 5 ml of medium. Cultures were inspected for the presence of motile spirochetes using a dark-field microscope (10×/40; Leica DM2500; Leica Microsystems GmbH).

Tissue samples for spirochete cultivation and qPCR

On day 49/50 post-spirochete inoculation, tissue samples from the ears, skin (site of inoculation), tibiotarsal joints, spleens, urinary bladders, hearts, and brains were aseptically removed from each euthanatized C3H/HeOuJ mouse. Tissue samples were immersed in 70% ethanol for 1 min and then washed with sterile phosphate-buffered saline (PBS) for 30 s. Ear and skin tissues were immersed in 70% ethanol for 2 min. After washing, tissues were cut into two approximately equal parts. Half of each sample was placed in a 1.5 ml microcentrifuge tube and frozen at −30 °C for later DNA extraction. For cultivation of spirochetes, the other tissue portion was transferred into a sterile Stomacher closure bag (Seward Laboratory, London, UK) containing 2 ml of Pettenkofer/LMU Bp medium without antibiotics for Bp or 2 ml of BSK-H complete medium without antibiotics for Bbss. Stomacher bags were processed at normal speed for 60 s with a Stomacher® 80 microBiomaster (Seward Laboratory). Subsequently, the medium and tissue samples were transferred into a 12 ml screw top tube (centrifuge tube 12; TPP, Faust Lab Science GmbH, Klettgau, Germany) prefilled with 8 ml of the same medium. Cultures were incubated at 37 °C (Bp) or 33 °C (Bbss) for six weeks and examined once per week with a dark-field microscope (10×/40; Leica DM2500; Leica Microsystems GmbH).

Detection of borrelial DNA in murine blood and tissue samples

All blood and tissue samples from the NOD-SCID and C3H/HeOuJ mice were subjected to DNA extraction and PCR detection according to published protocols [12]. The detection limits were 6.9 spirochetes/µl blood (Cq value of 39.900) and 3.0 spirochetes/mg tissue (Cq value of 39.372). A QuantStudio 5 real-time qPCR system (Applied Biosystems, ThermoFisher Scientific GmbH, Ulm, Germany) was used to amplify the DNA target genes flaB (Bp) [12] and ospA (Bbss) [43]. Oligonucleotide primer pairs and probes (Table 1) were synthesized by Eurofins Genomics (Ebersberg, Germany). Each qPCR reaction was set up in a 20 µl final volume (Table 2). The PCR programs consisted of (i) heating at 95 °C for 2 min for polymerase activation and DNA denaturation; (ii) amplification for 40 cycles with denaturation at 95 °C for 5 s and extension and annealing at 60 °C for 25 s; and (iii) a final step at 25 °C for 2 min in a 96 multiply PCR plate natural (Sarstedt AG & Co.).

Table 1.

Primers and probes utilized in this study

Primer name	Sequence (5′-3′)
Bp_flaB_fw	GAGGGTGCTCAACAAGCAA
Bp_flaB_re	CAACAGCAGTTGTAACATTAACTGG
Bp_flaB_probe	FAM-AAATCAGGAAGGAGTACAACCAGCAGCA-TAM
BbssN40-ospA 17 fw	AATGTTAGCAGCCTTGACGAGAA
BbssN40-ospA 119 re	GATCGTACTTGCCGTCTTTGTTT
BbssN40-ospA-41T	FAM-AACAGCGTTTCAGTAGATTTGCCTGGTGA-TAM

Table 2.

PCR mixture used in this study

PCR	Bp (flaB)		Bbss (ospA)
	Working concentration	Reaction volume (µl)	Working concentration	Reaction volume (µl)
Master mixa	1×	10	1×	10
Forward primer	600 nM	1.2	900 nM	0.64
Reverse primer	600 nM	1.2	900 nM	0.64
Probe	200 nM	0.8	100 nM	0.97
Reference dyeb		0.1	–	–
Nuclease-free water		4.2		5.25
Template DNA		2.5		2.5

^aQuantiNova probe PCR master mix (Qiagen, Hilden, Germany)

^bQN ROX reference dye (Qiagen)

Abbreviations: Bbss, Borrelia burgdorferi sensu stricto; Bp, Borrelia persica

To assess the copy numbers of the target genes in the blood and tissue samples, PCR-based standard curves were established with known amounts of double-stranded DNA (dsDNA) of the flaB or ospA gene synthesized by Metabion International AG (Planegg, Germany). Tenfold serial dilutions were made ranging from 1.0 × 10⁷ to 10¹ copies per reaction. Two positive controls of dsDNA (containing 1.0 × 10³ and 1.0 × 10⁵ copies of the Bp or Bbss target gene) and a no template control (NTC, 2.5 µl of nuclease-free water) were included in each run. Both standard template dsDNA and sample DNA from mouse blood and tissues were amplified in triplicate. Based on the obtained quantification cycle (Cq), the number of spirochetes per ml of blood or per mg of tissue was calculated using QuantStudio Design and Analysis Software (Applied Biosystems).

Antibody levels measured with a kinetic ELISA

ELISA plates were coated with whole-cell lysates from Bp or Bbss cultures, which had been sonicated and prepared as previously described [44, 45]. Pooled plasma samples and serum samples from individual mice were diluted at 1:100 with sample buffer (PBS) containing 0.05% Tween 20 (AppliChem GmbH, Darmstadt, Germany) and 2% nonfat dry milk (Merck KGaA, Darmstadt, Germany). A computerized kinetic ELISA was applied as described previously [46]. Peroxidase-conjugated goat anti-mouse immunoglobulins (IgG, IgA, and IgM; MP Biomedicals, LLC, Heidelberg, Germany) at a dilution of 1:4000 (for Bp) and 1:3000 (for Bbss) served as a secondary detection antibody. Each test included negative and positive controls. All plasma and serum samples were tested in duplicate, and mean values are reported.

Visualization of specific antibodies against Bbss via line immunoassay

Serum samples from individual mice collected on day 49/50 pi with Bbss were analyzed with a line immunoblot assay (LIA) to visualize specific antibodies against this agent. Briefly, IgG immunoblotting strips (Sekisui Virotech GmbH, Rüsselsheim, Germany) with the recombinant protein fractions (VlsE mix, OspA mix, DbpA mix, OspC mix, BmpA, p58, and p83/100) were prepared according to the manufacturer’s instructions. Serum samples were diluted 1:100 in the ready-to-use IgG immunoblot dilution/wash buffer (Sekisui Virotech GmbH). The same secondary antibody used in the ELISA was applied at a dilution of 1:1000, and strips were incubated for 30 min at room temperature. After three washing steps with the dilution/wash buffer and one time with distilled water, the color reaction was achieved by adding substrate solution (Opti-4CN Substrate Kit; Bio-Rad Laboratories GmbH, Munich, Germany) and stopped by washing the strips with distilled water three times. Images were taken with a Cemi-DocMP System and Image Lab Software Version 5.0 (Bio-Rad Laboratories GmbH).

Statistical analysis

All graphs in this study were prepared with OriginPro 2017 Software (Additive GmbH, Friedrichsdorf, Germany). Data are presented as the means and standard deviations (SDs).

Results

Population kinetics of host-adapted Borrelia in the blood of NOD-SCID mice

Two groups of six NOD-SCID mice each were challenged independently with an intradermal inoculation of in vitro cultured 1.0 × 10⁵Bp and 1.0 × 10⁶Bbss. The bacterial burden and viability of host-adapted Borrelia organisms were evaluated. On day 1 pi, the flaB gene of Bp (1.3 ± 0.2 × 10⁵ copies/ml) was detectable in the blood samples from mice receiving Bp, and viable spirochetes were observed in blood cultures from all six mice (30 µl of blood in corresponding cultures). The number of Bp kept increasing over time, although some minor declines occurred on day 4 (2.2 ± 1.7 × 10⁵ cells/ml), day 7 (1.8 ± 0.5 × 10⁶ cells/ml), and day 11 (3.6 ± 2.0 × 10⁶ cells/ml; Fig. 2a). Considering the numbers and viability of Bp organisms observed at various time points; day 12 (5.6 ± 1.2 × 10⁶ cells/ml blood) was identified as the optimal sampling time point to obtain spirochete-containing blood samples to be used for the subsequent challenge of immunocompetent C3H/HeOuJ mice. An additional five NOD-SCID mice were inoculated with Bp. Blood with 7.2 × 10⁶Bp per ml was harvested on day 12 pi (Fig. 2a). In the other group, Bbss organisms were detectable for the first time on day 2 (8.5 ± 1.4 × 10³ cells/ml) and reached 4.9 ± 3.3 × 10⁴ cells/ml blood on day 7, plateauing at a concentration of ~ 3.0 × 10⁴ cells/ml blood until day 17 pi (Fig. 2b). On day 10, sufficient numbers of spirochetes for subsequent infection experiments (3.9 ± 1.3 × 10⁴ cells/ml) were detected in blood samples. Two additional groups with five NOD-SCID mice each were inoculated intradermally with Bbss. On day 10 pi, blood from the five mice in each group was pooled, resulting in 3.5 × 10⁴ and 2.8 × 10⁴Bbss organisms per ml blood (Fig. 2b).

Fig. 2.

Kinetics of host-adapted Borrelia spp. in the blood of immunodeficient NOD-SCID mice over a course of 17 days. Mice were injected intradermally with cultured 1.0 × 10⁵Bp (a) or 1.0 × 10⁶Bbss (b) per animal. aBp was detectable on day 1 pi, with an increasing hematogenous spirochete burden over time. On day 12 pi, an average of 5.6 ± 1.2 × 10⁶ cells were detected per ml blood among six NOD-SCID mice. In five additional NOD-SCID mice, 7.2 × 10⁶Bp/ml blood was detected on day 12 pi. b The first Bbss in blood were detectable on day 2 (8.5 ± 1.4 × 10³ cells/ml), and concentrations climaxed at 4.9 ± 3.3 × 10⁴ cells/ml blood on day 7, plateauing at ~ 3.0 × 10⁴ until day 17 pi. On day 10 pi, the average borrelial load was 3.9 ± 1.3 × 10⁴ organisms per ml blood among six NOD-SCID mice. In two additional groups of five NOD-SCID mice, 3.5 × 10⁴ and 2.8 × 10⁴Bbss/ml blood were detected on day 10 pi

Distribution of host-adapted borreliae in tissues of immunodeficient NOD-SCID mice

Tissue samples collected on day 12 pi (Bp) or day 10 pi (Bbss) from the ear (only in the case Bbss-inoculated mice), skin (site of inoculation), tibiotarsal joint, spleen, urinary bladder, heart, and brain of each NOD-SCID were positive for borrelial DNA. In preceding (data not shown) experiments, the growth kinetics of Borrelia cultures was evaluated. The days 12 and 10 produced Borrelia in sufficient numbers and quality in the case of Bbss and Bp, respectively. Motile spirochetes, Bp and Bbss, were detected in culture medium cultivated with samples collected from the joints, spleens, bladders, hearts and brains. Detection of Bp and Bbss by culture failed in the case of all the ear and skin samples due to extensive bacterial contamination and overgrowth (Table 3).

Table 3.

Distribution of Borrelia persica and Borrelia burgdorferi sensu stricto spirochetes in tissues of immunodeficient NOD-SCID mice on day 49/50

Inoculuma	n	Spirochetes in tissue samples detected by culture/qPCR (organisms/mg)
		Ear	Skin	Joint	Spleen	Bladder	Heart	Brain
Intradermal
B. persica (1.0 × 105)		#/0	#/17	#/199	+/873	+/74,518	+/14,017	+/3702
		#/0	#/47,690	#/117	#/19	#/1743	#/46,102	#/10,721
		#/0	#/11,529	+/262	−/3381	+/83,700	+/23,582	+/11,929
		#/0	#/1171	#/574	+/1050	+/26,254	#/28,797	+/2639
		#/0	#/311	#/24	#/144	#/131,872	#/6168	#/1896
Positive mice	3/5	0/0	0/5	1/5	2/5	3/5	2/5	3/5
Intradermal
B. burgdorferi sensu stricto (1.0 × 106)		#/48	#/41,467	+/20,395	+/22	+/266,594	+/360	+/11
		#/522	#/18,795	+/37,393	+/537	+/217,600	#/333	+/12
		#/3082	#/16,655	#/2113	#/14	+/2,110,835	+/357	+/15
		#/10,372	#/18,435	+/40,571	#/3	+/1,141,583	+/1122	+/47
		#/4,987	#/15,288	+/17,693	+/992	+/384,204	+/2057	+/12
Positive mice	5/5	0/5	0/5	4/5	3/5	5/5	4/5	5/5

^aCulture-derived borreliae

Key: #, contaminated culture; +, positive, with motile spirochetes in culture; −, negative, no spirochetes in culture

Spirochetemia in immunocompetent C3H/HeOuJ mice

One hundred microliters of pooled blood that contained 7.2 × 10⁵ host-adapted Bp or 3.5/2.8 × 10³ host-adapted Bbss organisms was injected ID or strictly IV into C3H/HeOuJ mice. Throughout a 49/50-day study period, blood samples were collected at defined time points. All mice inoculated with Bp intradermally or intravenously showed Borrelia DNA signals until day 15 pi (Fig. 3); viable spirochetes were also observed in the blood during this period by dark-field microscopy. Bacterial concentrations increased in the blood to 8.3 ± 1.9 × 10⁵ (day 6) and 1.9 ± 1.7 × 10⁶ (day 12) organisms per ml in mice inoculated with Bp intradermally. Only one single animal inoculated intradermally with Bp was positive until day 18 (7.4 × 10⁴ cells/ml blood). Similarly, the mice inoculated intravenously with Bp demonstrated two peaks in spirochete population kinetics: 3.7 ± 2.4 × 10⁶ cells/ml blood on day 6 and 4.1 ± 6.8 × 10⁶ cells/ml blood on day 12. One single mouse produced 2.8 × 10⁵ and 3.8 × 10⁵Bp per ml blood on days 21 and 24, respectively (Fig. 3). Between day 27 and days 49/50, however, all mice were negative for Borrelia DNA, and no motile Bp organisms were recovered from 30 µl blood samples.

Fig. 3.

Kinetics of Bp DNA in the blood of immunocompetent C3H/HeOuJ mice during a course of 49/50 days. C3H/HeOuJ mice were challenged (a) intradermally or (b) via a strict intravenous route with 7.2 × 10⁵ host-adapted Bp spirochetes per animal. Blood samples were screened with a qPCR test method. Between day 27 and days 49/50, no spirochetal DNA was detected in blood samples of any mouse. Different symbols indicate levels in individual mice and horizontal lines indicate mean values per sampling day

In contrast, Bbss was not visible microscopically (dark-field) in blood samples collected from C3H/HeOuJ mice or in their pooled blood sample batches, regardless of whether the animals had been exposed to the spirochetes via the ID or IV route. Cultivation of 30 µl blood samples in 5 ml of BSK-H medium showed no growth of Bbss spirochetes over the period of a six-week incubation. Additionally, not a single Bbss-specific DNA signal was detected in any blood specimens collected from all immunocompetent C3H/HeOuJ mice after Bbss inoculation via the ID or IV route. This finding was highly statistically significant (Fisher’s exact test, P < 0.00001).

Borrelia distribution in tissues of immunocompetent C3H/HeOuJ mice

Bp organisms were observed in all cerebral tissue samples collected from immunocompetent C3H/HeOuJ mice (n = 11) on day 49/50 post-ID or IV spirochete inoculation (100%). The other tissue samples (those from the joint, spleen, urinary bladder, and heart) produced neither viable spirochetes in culture medium nor flaB gene signals in the PCR tests (Table 4). Bacterial contamination occurred in cultures with ten ear and eight skin tissue samples, while the rest of the samples (one ear and three skin tissue samples) showed no Bp growth (Table 4).

Table 4.

Distribution of Borrelia persica spirochetes in tissues of immunocompetent C3H/HeOuJ mice on day 49/50

Inoculuma	n	Spirochetes in tissue samples by culture/qPCR (organisms/mg)
		Ear	Skin	Joint	Spleen	Bladder	Heart	Brain
Intradermal
B. persica (7.2 × 105)		#/0	#/0	−/0	−/0	−/0	−/0	+/39
		#/0	#/0	−/0	−/0	−/0	−/0	+/31
		#/0	−/0	−/0	−/0	−/0	−/0	+/89
		#/0	#/0	−/0	−/0	−/0	−/0	+/59
		#/0	−/0	−/0	−/0	−/0	−/0	+/136
Positive mice	5/5	0/0	0/0	0/0	0/0	0/0	0/0	5/5
Intravenous
B. persica (7.2 × 105)		#/0	#/0	−/0	−/0	−/0	−/0	+/30
		#/0	#/0	−/0	−/0	−/0	−/0	+/34
		−/0	−/0	−/0	−/0	−/0	−/0	+/75
		#/0	#/0	−/0	−/0	−/0	−/0	+/216
		#/0	#/0	−/0	−/0	−/0	−/0	+/63
		#/0	#/0	−/0	−/0	−/0	−/0	+/74
Positive mice	6/6	0/0	0/0	0/0	0/0	0/0	0/0	6/6

^aHost-adapted borreliae

Key: #, contaminated culture; +, positive, with motile spirochetes in culture; −, negative, no spirochetes in culture

When Bbss was injected intradermally into immunocompetent C3H/HeOuJ mice, 100% of these animals were positive 50 days after the inoculation of host-adapted spirochetes, as shown by culture and qPCR (Table 5). Motile Bbss organisms were observed in medium cultured with tissue specimens from ears (4/11), skin samples (10/11), joints (11/11), spleens (4/11), bladders (11/11), hearts (11/11) and brains (2/11). Bbss-specific DNA was detected only in urinary bladders (11/11) and heart tissue samples (7/11) of these animals (Table 5). In strict contrast, all eleven mice that had intravenously received the host-adapted borreliae tested completely negative for viable Bbss organisms and borrelial DNA in any tissue sample (Table 5).

Table 5.

Distribution of Borrelia burgdorferi sensu stricto spirochetes in tissues of immunocompetent C3H/HeOuJ mice on day 49/50

Inoculuma	n	Spirochetes in tissue samples by culture/qPCR (organisms/mg)
		Ear	Skin	Joint	Spleen	Bladder	Heart	Brain
Intradermal
B. burgdorferi sensu stricto (3.5/2.8 × 103)		#/0	+/0	+/0	#/0	+/875	+/0	−/0
		#/0	+/0	+/0	+/0	+/676	+/0	+/0
		+/0	+/0	+/0	+/0	+/1041	+/409	−/0
		#/0	+/0	+/0	+/0	+/1867	+/0	+/0
		#/0	#/0	+/0	+/0	+/1482	+/0	−/0
		+/0	+/0	+/0	−/0	+/2420	+/893	−/0
		+/0	+/0	+/0	−/0	+/10,295	+/501	−/0
		+/0	+/0	+/0	−/0	+/1383	+/788	−/0
		#/0	+/0	+/0	−/0	+/2741	+/817	−/0
		#/0	+/0	+/0	−/0	+/906	+/109	−/0
		#/0	+/0	+/0	−/0	+/3487	+/607	−/0
Positive mice	11/11	4/0	10/0	11/0	4/0	11/11	11/7	2/0
Intravenous
B. burgdorferi sensu stricto (3.5/2.8 × 103)		#/0	−/0	−/0	−/0	−/0	−/0	−/0
		#/0	−/0	−/0	−/0	−/0	−/0	−/0
		#/0	#/0	−/0	−/0	−/0	−/0	−/0
		#/0	−/0	−/0	−/0	−/0	−/0	−/0
		#/0	−/0	−/0	−/0	−/0	−/0	−/0
		−/0	#/0	−/0	−/0	−/0	−/0	−/0
		−/0	#/0	−/0	−/0	−/0	−/0	−/0
		−/0	#/0	−/0	−/0	−/0	−/0	−/0
		#/0	#/0	−/0	−/0	−/0	−/0	−/0
		#/0	#/0	−/0	−/0	−/0	−/0	−/0
		#/0	#/0	−/0	−/0	−/0	−/0	−/0
Positive mice	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0

^aHost-adapted borreliae

Key: #, contaminated culture; +, positive, with motile spirochetes in culture; −, negative, no spirochetes in culture

Detection of specific antibodies against Bp and Bbss

To monitor the adaptive immune response against borrelia organisms during the infection period, Bp- or Bbss-specific antibody levels were measured with a kinetic ELISA (KELA). As shown in Fig. 4a, injection (ID and IV) of host-adapted Bp into immunocompetent C3H/HeOuJ mice elicited strong antibody responses. In both groups, antibody levels rose to 267.5 and 166.1 mean KELA (a computerized kinetic enzyme-linked immunosorbent assay) units on day 21 and decreased to 214.1 and 104.9 KELA units on day 24, respectively. Thereafter, antibody levels reached 300.1 (ID) and 264.5 (IV) KELA units, respectively until days 49/50. Due to the larger-volume serum samples obtained at necropsy on days 49/50, each animal was tested individually, and together, they produced mean values of 296.6 ± 103.1 (ID) and 208.7 ± 42.5 KELA units (IV).

Fig. 4.

Specific antibodies against borrelia organisms in C3H/HeOuJ mice serum. Specific antibodies against Bp (a) or Bbss (b) were induced in C3H/HeOuJ mice. a Both groups of mice, inoculated intradermally or intravenously with Bp, showed rising antibody levels until day 21 pi, followed by a slight decrease and a repeated increase until day 49/50 pi. Data for individual serum samples from single animals are represented for days 49/50 pi (bar symbols). b Mice inoculated intradermally with Bbss showed increasing levels of specific antibodies against Bbss. Data for individual serum samples from single animals are represented for days 49/50 pi (bar symbols). In contrast, specific antibodies against Bbss were not detected when mice received Bbssvia strict intravenous injection

Mice that had been injected intradermally with host-adapted Bbss organisms (both those injected with 3.5 and 2.8 × 10³ organisms/animal) showed a steady increase in antibody levels up to 510.3 mean KELA units on day 49/50 pi. Serum samples from individual animals collected on the final day of the experiment responded clearly in the ELISA, with 486.4 ± 60.2 units (Fig. 4b). In contrast, none of the mice injected intravenously with Bbss organisms produced any specific antibodies, and only 30-KELA-unit background level was measured. In individual serum samples collected on the final day, antibody levels ranged from 13.7 to 59.8 (average 29.8 ± 20.2) KELA units (Fig. 4b).

As shown in Fig. 5, individual serum samples from eleven immunocompetent, ID-injected mice reacted on a line immunoblot (LIA) with the following antigens, which are indicative of infection with borreliae belonging to the Bb complex: a strong signal with VlsE mix (10/10); strong/moderate signals with OspC mix (8/10), BmpA (7/10) and p58 (5/10); and weak signals with DbpA mix (10/10) and p83 (8/10). On the contrary, none of the serum samples from the IV-injected mice produced specific signals during line immunoblotting.

Fig. 5.

Representative IgG line immunoblots of individual serum samples from immunocompetent C3H/HeOuJ mice injected with host-adapted Bbss. Lanes show antibody signals of individual serum samples. Lanes 1–3: NC, plasma samples from three non-inoculated mice that served as a negative control group; Lanes 4–14: Bbss-IV, plasma collected from mice that received Bbssvia strict intravenous injection; Lanes: 15–24: Bbss-ID, plasma collected from mice that received Bbssvia intradermal injection

Discussion

Borrelia burgdorferi sensu stricto (Bbss) is a tick-transmitted spirochete that causes Lyme borreliosis in humans and animals. In a murine model, the ability of Bbss organisms to disseminate via the hematogenous route in a mammalian host was investigated. The fitness of Bbss to survive in blood and utilize this body fluid as a vehicle was compared to that of B. persica, a representative of tick-transmitted spirochetes that cause relapsing fever in humans and animals and are known for their ability to thrive in the blood circulation. However, before tick-transmitted microorganisms enter the blood stream, they must adapt to the new environment after they have been deposited into the dermis of the new host. Unlike insects (e.g. mosquitoes), ticks, as arachnids are pool feeders and deliver their germ-loaded saliva into the surrounding tissue, from where bacteria need to access the microvasculature if they depend on the circulation for further survival and growth. Alternatively, disease-causing organisms may stay in the tissue and use cells and extracellular matrices as passageways to distant body sites. During the time after the tick bite that spirochetes spend in the host’s dermis, the microorganisms undergo substantial reshaping of their outer surface coating [47], which is why host-adapted spirochetes were utilized for the experiments presented in this paper. Furthermore, the smallest injuries during inoculation, which offer spirochete access to tissues, are a starting point for further tissue-based colonization. Therefore, we opted to use microsurgery to obtain controlled access through the large jugular vein to avoid any damage to the endothelium lining the vasculature during strict intravenous spirochete injection. In this way, we avoided endothelial damage and unintentional deposition of spirochete in host tissue that are likely to occur following injection into the mouse’s tail vein. This infection model allowed us to clarify whether Bp and Bbss organisms are capable of entering and subsequently leaving the blood stream to colonize distant sites in mammals. The successful recultivation of Borrelia organisms from tissues sufficiently distant from the inoculation site is ample evidence of satisfactory virulence and dissemination capability of these spirochetes, especially in light of the discussion on disseminating and non-disseminating B. burgdorferi strains [22, 23, 48, 49]. The evaluation of all parameters, including tissue culture, PCR and antibody response during the experiments, indicated that the blood-bound Bbss spirochetes do not leave the blood stream and that the circulatory system is an impasse for Bbss, whereas Bp organisms are able to penetrate the vessels and disseminate further to distant tissues. For Bp, the brain tissue may serve as a reservoir [50].

As outlined above, borreliae must adapt physiologically to two different host environments during the course of its enzootic cycle between the arthropod vector and mammalian host [2, 47, 51]. Spirochete adaptation to the mammal milieu was necessary in our study to avoid the interference of any antigen (e.g. OspA) chiefly derived from in vitro cultivation [52]. Therefore, immunodeficient NOD-SCID mice were utilized to generate the host-adapted Bp and Bbss spirochetes because these mice lack mature T and B cells and complement activity [32], which allow higher bacterial burdens in the blood stream than those affected by the immune responses of immunocompetent animals [24, 34, 53]. Support for the contention regarding antigen expression in vivo comes from our further experiment with immunocompetent mice, which were infected with these host-adapted Bbss organisms but failed to produce specific antibodies against OspA (Fig. 5).

In the blood of immunodeficient NOD-SCID mice, Bp was detectable on day 1 after injection and at a higher concentration than Bbss, which was detectable on day 2 after inoculation of culture-derived borreliae. Up to 8.8 ± 1.2 × 10⁶ spirochetes per ml blood (on day 17) was observed in the case of Bp; Bbss concentrations, however, climaxed at 4.9 ± 3.3 × 10⁴ cells/ml on day 7 pi (Fig. 2). Hence, it seems that Bp is more robust than Bbss in adaptation and replication in the blood of immunodeficient mice given that a 10-fold lower inoculum of Bp organisms than Bbss (10⁶ organisms/mouse) was injected into these animals. On day 12 or day 10 pi, spirochetes were present in various tissues of infected NOD-SCID mice, as shown by in vitro cultivation and qPCR (Table 3), indicating robust spirochete proliferation in tissues of immunodeficient animals.

Bp spirochetes in the blood of immunocompetent C3H/HeOuJ mice were detectable up to 24 days after either ID or strict IV inoculation with 7.2 × 10⁵ host-adapted Bp organisms. Fluctuations in spirochete numbers during this period (Fig. 3) might be due to the appearance of specific antibodies, which increased until day 21, followed by a slight decline until day 24 (Fig. 4a). Spirochetemia for Bp was not documented beyond day 24, while at the same time, high antibody levels increased until day 49/50. However, these antibodies were not able to eliminate Bp infection in brain tissue (Table 4), which is an immune-privileged site where no tissue damage or clinical signs were induced by Bp [12]. Consistent with other TBRF Borrelia spp. (e.g. B. duttonii, B. turicatae, B. crocidurae and B. hispanica) that show residual brain infection [54], Bp spirochetes, though faced with mammalian host immunity, also show this tropism regardless of the inoculation route (ID or IV). Obviously, Bp can survive and multiply in the blood stream, and the microvasculature does not present a barrier for Bp.

Similarly, when Bbss was inoculated intradermally, specific antibodies were produced during the infection (Figs. 4, 5), and viable spirochetes were recovered from various tissues samples (Table 5). In sharp contrast, neither Bbss DNA nor motile spirochetes were detected in the blood samples. Inoculated host-adapted Bbss spirochetes (3.5 × 10³ or 2.8 × 10³ per animal) initiated a robust infection and were able to invade distant tissue sites in immunocompetent mice following ID inoculation. Although single tissue samples showed culture-positive but PCR-negative results for Bbss (Table 5), the possible reason might be that Bbss-specific DNA in the samples was present at a very low level, which might have been below the detection limit of the qPCR applied in this study. This hypothesis is supported by the finding that even one single viable spirochete may be recovered by culture from a tissue sample, whereas it is not possible to detect the borrelial DNA in a single cell by PCR [55]. Bbss appears to only infrequently target the brain tissue but prefers to persist in tissues such as the skin, bladder, joint, and heart of immunocompetent mice following ID challenge, consistent with prior reports dealing with LB infection in humans and animals [56, 57].

In the experiments presented here, Bbss spirochetes were inoculated via a strict intravenous route at a dose of 2.8 to 3.5 × 10³ organisms per animal. This infection may mimic the spirochetemia phase, which is detected infrequently in blood samples from patients during early LB infection [22, 58]. Our results (Table 5) suggest that these Bbss organisms are cleared by the animals’ innate immunity [59, 60]. The lack of Bbss-specific antibodies in the course of the intravenous injection strongly suggests that these spirochetes did not even multiply or provide sufficient antigen to stimulate the host B cell population. However, LB spirochetes inoculated into the skin can persist and multiply locally and disseminate to distal sites [61]. During dissemination, the blood seems to play no role because Bbss organisms were not detected in any blood sample. Instead, skin and connective soft tissues probably serve as critical intermediate media for spirochete spread. This hypothesis is further supported by the observations that LB borreliae were only occasionally or not at all re-isolated from peripheral blood of immunocompetent animals even when a persistent infection was established, regardless if it was initiated by a low-inoculum (10³, 10⁴, intradermal injection) or high-inoculum (10⁸, subcutaneous injection) dose [34, 53, 62]. In addition, Shih et al. [56] stated that the expanding EM seems to represent the advancing front of a wave of the spirochetal organisms ‘dermatogenously’ migrating outward from the deposition site in the skin of the human host. They and others [63] have also highlighted the issue that prompt excision or topical treatment with antibiotics applied in the site of murine skin shortly after tick exposure or needle inoculation can avert systemic infection. Moreover, immunosuppression with dermocorticoid clobetasol reactivated LB Borrelia abundance in the skin tissue, while the blood still remained spirochete negative [61]. In contrast, high levels of spirochetemia were achieved in the course of a TBRF infection (persistently infected brain tissues as source for spirochetes) when a state of immunosuppression was initiated [50]. Furthermore, the large numbers of genes (e.g. decorin-binding proteins (Dbps), such as DbpA and DbpB, and the fibronectin-binding protein BBK32), which are selectively expressed by LB spirochetes in mammalian hosts, need to be considered, which contribute to the spirochetes’ dissemination and colonization of target tissues [64].

Borreliae are frequently found in certain tissues since they depend on essential substrates, such as N-acetylglucosamine (NAG) [65]. In mammals, NAG is a substrate for hyaluronan synthesis [66] and consequently present in certain tissues at varying concentrations. Thus, it is likely that Borrelia organisms invade organs, e.g. joints and other tissues containing NAG. However, a subpopulation of Borrelia organisms remains in the skin and consequently is able to infect ticks attached to the skin.

Despite the results presented here, an earlier study with a similar experimental setup still came to the conclusion that Bbss disseminates hematogenously. Gabitzsch et al. [67] supposedly intravenously injected the spirochete inocula. Uncontrolled injection, as outlined earlier, carries the risk of depositing spirochetes in the surrounding tissues when retracting the needle from the animal. Interestingly, the authors state clearly that in cases where intravenous injection was not successful, an IP injection was performed [67]. Obviously, their results were obtained by IP rather than by IV injection, thus may lead to a misinterpretation of the data and do not clarify how Bbss disseminates from the injection site to the distant tissues. In our study, microsurgery avoided vessel damage and spillover of Borrelia-containing blood into the surrounding tissues (Additional file 1: Video S1). Other studies [68, 69] utilized huge doses of Bbss spirochetes (culture-derived and up to 4 × 10⁸ per animal) for IV inoculation, arguing that hematogenous spread is the result of few interactions between spirochetes and endothelial cells under shear force conditions within a short time period (5–45 min). The puzzling results of these studies with enormous inocula were also contested by other authors [70], since the maximal concentration of LB spirochetes achievable in suitable culture medium is ~ 10⁸–10⁹ per ml [71, 72]. In comparison, only a small number of spirochetes per injection site (up to 10³ organisms) is deposited into the dermis of mice after tick attachment [61, 73–76]. Hence, not only the strict IV inoculation but also a reasonable inoculum dose plays the most crucial role in establishing a reliable murine model and drawing a realistic conclusion. Our relatively low inoculum size for Bbss may faithfully reflect the actual pathophysiological conditions during natural infection after a tick bite. We also speculate that in the case of Bp, our infection dose of 7.2 × 10⁵ organisms per mouse approximates human and animal infections in the field since the observed spirochetemia in our experimental animals closely mimics the situation reported for blood samples retrieved from human TBRF cases and other laboratory experimental animals [6–9].

Another controversial aspect regarding the spirochetal dissemination route is the question of whether blood transfusion is safe in the context of Bp and Bbss transmission. Relapsing fever spirochetes have been well documented in a few blood transfusion-mediated cases [77–79], as well as other tick-borne agents, such as Ehrlichia spp. [80] and Babesia spp. [81]. In addition, B. hermsii, a TBRF-causing species, has been shown to induce spirochetemia after intravenous inoculation into immunocompetent animals [82, 83]. Babesia miyamotoi, a newly recognized TBRF spirochete transmitted by Ixodes spp. ticks in the USA and Europe, where LB is endemic, have also been demonstrated to produce transfusion-transmitted infections in immunocompetent mice, suggesting the possibility of transfusion transmission of this species in people [84]. However, to date, there is no report of natural blood transfusion-mediated transmission of B. burgdorferi, despite the ability of spirochetes to survive in blood samples for prolonged time periods under blood bank conditions [85–87]. Our findings of the inability of Bbss to leave the blood stream may answer this question, and we argue that the risk of acquiring LB by blood transfusion should be considered nonexistent. However, a transfusion of TBRF-causing Bp is highly problematic.

In future studies, it would be of interest if an experiment was performed with additional Borrelia species to evaluate the potential strain differences. Here, we report on a proof of principle. However, it is not expected that various strains of Bbss should behave differently when they are injected directly into the blood stream, as performed in this study. Other researchers, (e.g. [88–90]), who have reported on the variable behavior of different Bbss strains, did not apply a strict intravenous injection protocol, as applied in this study. Thus, the data obtained from this study cannot be compared with the results described in the publications mentioned above. The deposition of Bbss into the skin and subsequent colonization of the injection site will subsequently establish a depot effect. Borrelia organisms will multiply in the days following the injection, and a large number of spirochetes have the chance to enter into the circulation for an extended time period, resulting in an accumulation of spirochetes in the blood until they are cleared by the host. In contrast, in a single spirochete bolus (100 µl volume) that is injected intravenously, the number of organisms will not increase over time (according to the hypothesis stated in this paper). Most likely, the number will decrease due to the host’s non-specific immune response. As a consequence, such a small number of spirochetes in a given blood sample is difficult to detect. A potential drawback of this study is the lack of an experiment that checks whether a strict IV protocol compromises the infectivity of Bbss. In the view of the authors, this possibility is unlikely.

Conclusions

In conclusion, our results provide new insights into the dissemination routes of Bp and Bbss. Bp is able to translocate in mammalian hosts via the blood stream, whereas Bbss is unable to spread hematogenously and establish an infection via that route, consequently relying on tissue migration instead. However, our studies on LB are limited to the Bbss species. Further studies that include B. afzelii and B. garinii spirochetes, which cause different clinical manifestations of LB [91–93], are necessary to explore further dissemination pathways to better understand how Borrelia spp. interact with host cells.

Abbreviations

LD

Lyme disease

Bb

Borrelia burgdorferi

Bbss

Borrelia burgdorferi sensu stricto

IV

intravenous

TBRF

tick-borne relapsing fever

IP

intraabdominal

Authors’ contributions

LL designed and performed the experiments, analyzed the data, and wrote the manuscript. LS and TPNT contributed to the experiments. JW, SF and SU contributed to manuscript drafting. RKS conceived the project, provided the conceptual design, and contributed to manuscript drafting. All authors read and approved the final manuscript.

Funding

LL (award No. 201406300038) received a four-year scholarship from the China Scholarship Council (CSC). The funders were not involved in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

Data supporting the conclusions of this article are included within the article and its additional file. Further data of interest will be available from the corresponding author upon request.

Ethics approval and consent to participate

This study was carried out in compliance with the European Health Law of the Federation of Laboratory Animal Science Associations (FELASA) and German animal welfare law. All animal care and use protocols were approved and permitted by the District Government of Upper Bavaria (approval number: AZ55.2-1-54-2532-144-2015).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests. The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary information

Supplementary information accompanies this paper at 10.1186/s13071-020-04060-y.